VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 19, 2014) -


Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) ("Calyx" or the "Company") is pleased to announce a non-brokered private placement of up to 6,000,000 common shares of Calyx ("Calyx Shares") at a price of $0.05 per Calyx Share for cash proceeds of up to $300,000 (the "Private Placement"). The Company may pay cash finders' fee of up to 7% and issue finders' warrants of up to 5% of the number of Calyx Shares placed, on all or a portion of the Private Placement. Any finders' warrants issued will enable the holder to purchase one Calyx Share for a period of one year at a price of $0.15. The funds raised from the issuance of the Calyx Shares will be for general working capital and corporate development purposes.

About Calyx

Calyx Bio-Ventures Inc. (TSX VENTURE:CYX) Calyx owns a portfolio of proprietary intellectual property with applications in crop enhancement, and has an approximate shareholding of approximately 25% in Agrisoma Biosciences Inc., a company which is producing a non-food energy feedstock crop for biofuel production. The Company has also entered into a letter of intent to acquire all of the outstanding shares of Cannigistics Agri-Solutions Corp., a company that is presently developing an enterprise software platform tailored to advanced indoor agriculture. For further information about Calyx, please visit

Forward-Looking Statements: This document contains certain forward-looking statements concerning Calyx, as well as other expectations, plans, goals, objectives, information or statements about future events, conditions, or performance that may constitute "forward-looking statements" or "forward-looking information" under applicable securities legislation. Such statements or information involve substantial known and unknown risks and uncertainties, certain of which are beyond Calyx's control, including the completion of the Private Placement and the delay or failure to receive regulatory approvals.

Such forward-looking statements or information are based on a number of assumptions, which may prove to be incorrect. In addition to other assumptions identified in this news release, assumptions have been made regarding, among other things, timing and completion of the Private Placement, the actual use of proceeds, and the timing of receipt of regulatory approvals.

Although Calyx believes that the expectations reflected in such forward-looking statements or information are reasonable, undue reliance should not be placed on forward-looking statements because Calyx can give no assurance that such expectations will prove to be correct. Forward-looking statements or information are based on current expectations, estimates and projections that involve a number of risks and uncertainties which could cause actual results to differ materially from those anticipated by Calyx and described in the forward-looking statements or information.

The forward-looking statements or information contained in this news release are made as of the date hereof and Calyx undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise unless so required by applicable securities laws or the TSX Venture Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

This press release shall not constitute an offer to sell, nor the solicitation of an offer to buy, any securities in the United States, nor shall there be any sale of securities mentioned in this press release in any state in the United States in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

Calyx Bio-Ventures Inc.
Don Konantz
President & CEO

Investor Relations:
Keir Reynolds